Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mohammad Qureshi

Cardiovascular Disease Beverly Hills, MI Medical Doctor

NPI 1982684254 CMS profile 90183

32804 Pierce St, Beverly Hills, MI 48025

Open in the dashboard

General payments

$33,212

683 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mohammad Qureshi of Beverly Hills, MI is reported in the CMS Open Payments database as having received $33,212 across 683 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,336 119
2024 General $7,375 136
2023 General $3,361 132
2022 General $3,078 113
2021 General $2,181 90
2020 General $1,859 37
2019 General $12,021 56

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mohammad Qureshi
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Mohammad Qureshi were reported at $3,336. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Mohammad Qureshi Cardiovascular Disease median Middle half National median
2019 $12,021 $450 $127–$1,392 $163
2020 $1,859 $242 $77–$751 $114
2021 $2,181 $335 $101–$1,037 $132
2022 $3,078 $395 $121–$1,211 $149
2023 $3,361 $443 $136–$1,283 $160
2024 $7,375 $450 $136–$1,323 $164
2025 $3,336 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $11,204 66 payments
  2. Lexicon Pharmaceuticals, Inc. $3,265 2 payments
  3. Abbott Laboratories $2,530 20 payments
  4. Amgen Inc. $1,836 75 payments
  5. AstraZeneca Pharmaceuticals LP $1,606 83 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $1,533 72 payments
  7. Janssen Pharmaceuticals, Inc $995 40 payments
  8. Lilly USA, LLC $927 33 payments
  9. Kestra Medical Technology Services, Inc. $917 28 payments
  10. E.R. Squibb & Sons, L.L.C. $912 61 payments
  11. Other $7,486 203 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $18,308 662 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $9,910 5 payments
  3. Consulting Fee $3,210 1 payment
  4. Education $1,141 13 payments
  5. Travel and Lodging $643 2 payments
Products named General payments · program years 2019–2025
  1. ENTRESTO $10,831 45 payments
  2. Repatha $1,560 63 payments
  3. BRILINTA $1,161 66 payments
  4. VERQUVO $1,111 53 payments
  5. XARELTO $995 40 payments
  6. MOUNJARO $827 28 payments
  7. JARDIANCE Diabetes $760 39 payments
  8. Assure WCD $757 24 payments
  9. JARDIANCE Diabetes $724 31 payments
  10. LifeVest $709 27 payments
  11. Other $10,860 310 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 58 drugs

Part D claims

5,783

Median for Cardiology: 2,533

Drug cost

$1,772,351

Median for Cardiology: $485,213

Branded share of claims

39.9%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 341 $334,530
Entresto Sacubitril/Valsartan Brand 222 $245,173
Eliquis Apixaban Brand 207 $223,547
Mounjaro Tirzepatide Brand 137 $185,269
Farxiga Dapagliflozin Propanediol Brand 153 $143,885
Xarelto Rivaroxaban Brand 116 $130,191
Repatha Sureclick Evolocumab Brand 155 $110,479
Ozempic Semaglutide Brand 87 $103,074
Camzyos Mavacamten Brand 13 $98,362
Verquvo Vericiguat Brand 12 $23,354

The 10 drugs with the highest cost, of 58 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 63 billing codes

Paid by Medicare

$190,819

Of which drugs: $604

Medicare patients

377

Average age 74

Services billed

1,994

200 women, 177 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 70%
Arthritis 53%
Diabetes 51%
Heart failure 49%
Chronic kidney disease 45%
Atrial fibrillation 33%
COPD 29%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 30 120 $604

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Repatha
  • Amgen Inc. $410
$410 178 —
MOUNJARO
  • Lilly USA, LLC $311
$311 137 —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $298
$298 341 —
VERQUVO
  • Merck Sharp & Dohme Corporation $226
$226 12 —
XARELTO
  • Janssen Pharmaceuticals, Inc $183
$183 116 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

683 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record